formoterol

Uses your system voice; voice and rate in settings.

Q637247Snapshot

≈ 3 min read

Names in other languages

  • DeutschFormoterol
  • Englishformoterol
  • euFormoterol
  • Françaisformotérol
  • Magyarformoterol
  • Nederlandsformoterol
  • Polskiformoterol
  • 日本語ホルモテロール

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Formoterol, also known as eformoterol, is a long-acting β 2 agonist (LABA) used as a bronchodilator in the management of asthma and chronic obstructive pulmonary disease (COPD). Formoterol has an extended duration of action (up to 12 h) compared to short-acting β 2 agonists such as salbutamol (albuterol), which are effective for 4 h to 6 h. Formoterol has a relatively rapid onset of action compared to other LABAs, and is effective within 2-3 minutes. The 2022 Global Initiative for Asthma report recommends a combination formoterol/inhaled corticosteroid inhaler as both a preventer and reliever treatment for asthma in adults. In children, a short-acting β 2 adrenergic agonist (e.g., salbutamol) is still recommended. It was patented in 1972 and came into medical use in 1998. It is available as a generic medication. It is also marketed in the combination formulations budesonide/formoterol and mometasone/formoterol.

Formoterol, also known as eformoterol, is a long-acting β 2 agonist (LABA) used as a bronchodilator in the management of asthma and chronic obstructive pulmonary disease (COPD). Formoterol has an extended duration of action (up to 12 h) compared to short-acting β 2 agonists such as salbutamol (albuterol), which are effective for 4 h to 6 h. Formoterol has a relatively rapid onset of action compared to other LABAs, and is effective within 2-3 minutes. The 2022 Global Initiative for Asthma report recommends a combination formoterol/inhaled corticosteroid inhaler as both a preventer and reliever treatment for asthma in adults. In children, a short-acting β 2 adrenergic agonist (e.g., salbutamol) is still recommended. It was patented in 1972 and came into medical use in 1998. It is available as a generic medication. It is also marketed in the combination formulations budesonide/formoterol and mometasone/formoterol.

Side effects

In November 2005, the US Food and Drug Administration (FDA) released a health advisory alerting the public to findings that show the use of long-acting β 2 agonists could lead to a worsening of wheezing symptoms in some patients. Nowadays, available long-acting β 2 agonists include salmeterol, formoterol, bambuterol, and sustained-release oral salbutamol. Combinations of inhaled steroids and long-acting bronchodilators are becoming more widespread – combination preparations include fluticasone/salmeterol and budesonide/formoterol.

Mechanism of action

Inhaled formoterol works like other β 2 agonists, causing bronchodilation by relaxing the smooth muscle in the airway so as to treat the exacerbation of asthma. It has also been reported to target tubulin, favorizing its polymerization.

Uses and combinations

Arformoterol ((R,R)-(−)-formoterol) — an enantiopure compound used in the management of COPD Combination drugs: Aclidinium bromide/formoterol Beclometasone/formoterol Budesonide/formoterol Mometasone furoate/formoterol

References

pnb:آمو دریا

Text derived from https://en.wikipedia.org/w/index.php?oldid=1329254941 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.